FDA Approves Tudriqev for Advanced Melanoma Treatment
The U.S. Food and Drug Administration has granted accelerated approval for Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy aimed at treating advanced, refractory melanoma. This therapy is specifically indicated for adult patients with unresectable advanced cutaneous melanoma who have experienced disease progression following a regimen involving PD-1 blocking antibodies. The decision is backed by clinical trial data indicating that approximately one in four patients responded positively to the treatment, with a median response duration of nearly 14 months. This offers a significant new option for a patient population that has faced limited treatment alternatives.
Karim Mikhail, Acting Director of the Center for Biologics Evaluation and Research, emphasized the urgency of this approval, stating that for patients with advanced melanoma resistant to PD-1 therapy, prognosis can be dire. He noted that clinicians are acutely aware of the pressing need for effective treatments in this challenging area.
Tudriqev is an innovative therapy based on a modified herpes simplex virus type 1 (HSV-1) that selectively targets and destroys cancer cells. Upon entering a tumor, the virus replicates, breaking apart cancer cells while simultaneously activating the body’s immune response to recognize and attack the cancer. When combined with nivolumab, an established anti-PD-1 immunotherapy, Tudriqev may help restore an effective immune response in patients whose cancer has previously stopped responding to immunotherapy.
The treatment involves injecting Tudriqev directly into tumors every two weeks for a total of eight doses, with the dosage tailored to the tumor size. A lower concentration is used for the initial dose, followed by higher concentrations for subsequent doses. Nivolumab is administered intravenously starting in the third week of treatment.
Megha Kaushal, Acting Deputy Director of the CBER Office of Therapeutic Products, remarked that this approval represents a new opportunity for patients who have exhausted their immunotherapy options, grounded in early evidence and the accountability required by the accelerated approval process.
The safety and efficacy of Tudriqev were evaluated in an open-label, multiregional, single-arm trial that included 140 adult patients with Stage IIIB, IIIC, or IV unresectable advanced melanoma who had shown disease progression after at least eight weeks of prior anti-PD-1 therapy. Of the 91 patients assessed, 24% achieved an objective response, with a median duration of 14.1 months.
Common adverse reactions reported in over 10% of patients included fatigue, fever, infections, chills, musculoskeletal pain, nausea, and others. Notably, there are safety warnings regarding the risk of transmitting a herpes infection to close contacts, as well as the potential for herpes infection to develop or reactivate in patients, alongside complications related to the injection procedure.
The FDA's approval process included a meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee, which featured public hearings with patients, advocates, and experts. Replimune, Inc. received the approval under the FDA’s accelerated pathway, which is contingent upon conducting further trials to confirm the clinical benefits of Tudriqev. Continued approval may depend on the outcomes of these confirmatory studies.




